Miles Trupp, PhD, has been working on investigating Parkinson’s Disease (PD) since his doctoral studies at the Karolinska Institute in Stockholm, where he focused on the neuroprotective activities of neurotrophic factor (GDNF) derived from supporting glial cells. As a postdoctoral fellow at the University of California, San Francisco, Dr. Trupp studied the molecular genetic response to dopamine medications, and he worked on metabolomics analysis of human clinical samples at SRI, International in Menlo Park. Since 2011, Dr. Trupp has focused on the use of mass spectrometry to identify early biomarkers for PD in CSF and plasma from biobanks of people with parkinsonian disorders. He believes that disease-modifying therapeutics, such as GDNF, will perform better in clinical trials if subjects are stratified into subgroups based on distinct molecular profiles. He is currently leading research focused on metabolomic and proteomic identification of novel targets in clinical samples from pre-diagnostic biobanks in Sweden.